Stockscreener 앱 받기
8.56
1.30%
0.11
시장 영업 전:
8.48
-0.08
-0.93%
Karyopharm Therapeutics Inc 주식(KPTI)의 최신 뉴스
Karyopharm to seek label expansion for Xpovio in myelofibrosis after late-stage trial win - MSN
KPTI stock slumps pre-market even as Karyopharm’s myelofibrosis treatment meets primary endpoint — retail doubtful about FDA approval - MSN
Karyopharm Therapeutics (KPTI) price target decreased by 22.08% to 12.24 - MSN
Karyopharm Therapeutics jumps 18%, raises $30M privately - MSN
Karyopharm Therapeutics (KPTI) affiliated managers report 1.9%–2.3% stakes - Stock Titan
[ARS] Karyopharm Therapeutics Inc. SEC Filing - Stock Titan
Karyopharm (KPTI) seeks approval for director slate and larger equity plans - Stock Titan
Gains Report: Can Karyopharm Therapeutics Inc disrupt its industry2026 Investor Takeaways & Daily Profit Maximizing Tips - baoquankhu1.vn
KPTI Receives Reiterated "Buy" Rating from HC Wainwright & Co. | KPTI Stock News - GuruFocus
Portfolio Update: Will Karyopharm Therapeutics Inc stock benefit from M A2026 Stock Rankings & Safe Entry Point Identification - baoquankhu1.vn
Quarterly Earnings: How sensitive is Karyopharm Therapeutics Inc to inflationPortfolio Gains Report & AI Enhanced Trading Alerts - baoquankhu1.vn
RBC Capital Adjusts Karyopharm Therapeutics PT to $16 From $23, Maintains Outperform Rating - Moomoo
Dip Buying: Is Karyopharm Therapeutics Inc attractive for institutional investors2026 Update & Growth Oriented Trading Recommendations - baoquankhu1.vn
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
RA Capital (NASDAQ: KPTI) and partners report 9.99% stake in Karyopharm - Stock Titan
Commodore Group discloses 1.95M KPTI stake; 19,618,032 shares O/S - Stock Titan
Karyopharm Therapeutics Inc. R (25K0.DU) insider ownership and holdings - Yahoo Finance Australia
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Short Interest Up 20.9% in March - MarketBeat
Will Karyopharm Therapeutics Inc benefit from green energy policiesInsider Buying & Safe Capital Growth Trade Ideas - baoquankhu1.vn
Piper Sandler Lowers Price Target for Karyopharm Therapeutics (K - gurufocus.com
Piper Sandler Reaffirms "Overweight" Rating for Karyopharm Therapeutics (NASDAQ:KPTI) - MarketBeat
Karyopharm stock price target cut to $8 by Piper Sandler on trial results - ca.investing.com
Karyopharm Therapeutics Inc (KPTI) Stock Price, Quote, News & History - benzinga.com
Karyopharm Strengthens Liquidity With New Equity Financing - tipranks.com
Karyopharm Therapeutics raises $30 million in private placement with RA Capital - Investing.com Australia
Karyopharm Therapeutics raises $30 million in private placement with RA Capital By Investing.com - Investing.com South Africa
Karyopharm Therapeutics (KPTI) Stock Jumps 6.9%: Will It Continue to Soar? - Yahoo Finance
HC Wainwright Has Optimistic Outlook of KPTI Q1 Earnings - MarketBeat
Karyopharm Therapeutics raises ~$30M in private placement, adds ~$19.8M via ATM - TradingView
Karyopharm (NASDAQ: KPTI) completes $30M private placement and ATM sale - Stock Titan
Karyopharm: Putting The Phase 3 Trial In Context (NASDAQ:KPTI) - Seeking Alpha
KPTI Stock Down on Mixed Phase III Myelofibrosis Combo Study Data - Yahoo Finance
KPTI: Baird Lowers Price Target, Maintains Outperform Rating | K - GuruFocus
Karyopharm Therapeutics (NASDAQ:KPTI) Price Target Lowered to $15.00 at Robert W. Baird - MarketBeat
HC Wainwright Lowers Karyopharm Therapeutics (NASDAQ:KPTI) Price Target to $8.00 - MarketBeat
H.C. Wainwright cuts Karyopharm stock price target on trial results By Investing.com - Investing.com Canada
HC Wainwright & Co. Lowers Price Target on Karyopharm Therapeuti - GuruFocus
Karyopharm raises $30M in private placement with RA Capital By Investing.com - Investing.com Australia
Karyopharm Therapeutics Falls As Pivotal Trial Hits Spleen Goal But Misses Symptom Mark - Sahm
Karyopharm Therapeutics Inc. (KPTI) Discusses Top Line Results From Phase III SENTRY Trial in MyelofibrosisSlideshow (NASDAQ:KPTI) 2026-03-25 - Seeking Alpha
Karyopharm myeloma drug yields mixed data in myelofibrosis trial - BioPharma Dive
Karyopharm’s myelofibrosis trial meets one of two primary goals By Investing.com - Investing.com India
KPTI Shares Fall Following Varied Results from Phase III Myelofibrosis Combination Study - Bitget
Karyopharm Therapeutics falls as pivotal trial hits spleen goal but misses symptom mark - msn.com
2.69%
0.25%
자본화:
|
볼륨(24시간):